JACOBIO-B (01167) has released its interim results for the six months ended June 30, 2026, reporting revenue of RMB 731 million, a substantial increase of 1,500.5% year-on-year. The company recorded a profit attributable to shareholders of RMB 601 million, a sharp turnaround from the loss of RMB 58.994 million reported in the same period last year, with basic earnings per share reaching RMB 0.78.

The revenue surge is primarily attributed to the strategic collaboration with AstraZeneca AB covering the global research, development, manufacturing, and commercialization of JAB-23E73, as well as the out-licensing and service agreements with AILISI for the research, development, production, and commercialization of Airca and sitneprotafib.